MEKINIST 1mg film-coated tablets medication leaflet

L01EE01 • trametinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mitogen-activated protein kinase (MEK) inhibitors

Trametinib is a MEK kinase inhibitor used in the treatment of advanced or metastatic melanoma with BRAF V600 mutations. It works by blocking the MAPK/ERK signaling pathway, which is hyperactivated in tumor cells with BRAF mutations, thereby inhibiting their growth and proliferation.

Trametinib is administered orally, usually once daily, with the dose adjusted based on patient response and tolerability. It is often used in combination with dabrafenib, a BRAF inhibitor, to enhance treatment efficacy.

Common side effects include skin rashes, diarrhea, fatigue, nausea, and peripheral edema. In rare cases, severe adverse reactions such as cardiomyopathy, pulmonary function impairment, or ocular toxicity may occur. Regular monitoring of cardiac function and other clinical parameters is essential during treatment.

Trametinib is an innovative therapeutic option for patients with advanced melanoma, contributing to prolonged survival and improved quality of life.